A clinical-stage immuno-oncology company with the potential to significantly disrupt the current cell therapy landscape. The Company is developing a portfolio of non-genetically modified, multi-antigen T cell therapies, which are able to recognize and kill heterogeneous tumors more effectively than conventional single-antigen CAR-T/TCR approaches. Compared to current engineered CAR-T therapies, Marker's products could potentially be less expensive, easier to manufacture, be less toxic and show clinical benefit with less cell volume and faster administration time.
Marker's current MultiTAA cell therapy is looking to initiate a Phase II study in AML in 2019. Additionally, TPIV200, a T-cell vaccine is currently in Phase 2 for ovarian cancer and triple-negative breast cancer. Lastly, is TPIV110/110 in Phase 1B in HER2/neu+ breast cancer.
Phase l or ll
100MM - 500MM
3200 Southwest Fwy #2240, Phoenix Tower
Houston, TX 77027
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by